RV-01

What is RV-01?

RV-01 (177Lu-BetaBart) is a radioimmunoconjugate consisting of a monoclonal antibody against B7-H3 (CD276) conjugated to lutetium Lu 177. The antibody binds B7-H3 on tumor cells and delivers cytotoxic beta radiation. It is studied in multiple cancers including prostate, colorectal, lung, ovarian, cervical, endometrial, breast, head and neck, esophageal, and sarcoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

177Lu-BetaBart

Drug type

Radiopharmaceutical

Targets

B7-homolog 3 (CD276) (antigen)

Mechanism

Kills target cells, directed at B7-homolog 3 (CD276)

Therapy area

Oncology

In trials of

MEDP

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Castration-Resistant Prostate Cancer (CRPC)Cervical CancerColorectal CancerEndometrial CancerEsophageal Squamous Cell Carcinoma (ESCC)Head &Amp; Neck Squamous Cell Carcinoma (HNSCC)NSCLC (Non-small Cell Lung Cancer)Ovarian CancerSarcomaSmall Cell Lung Cancer (SCLC )TNBC, Triple Negative Breast Cancer

Other drugs acting on CD276

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT07189871

Updated Oct 3, 2026.